Abstract
The promyelocytic leukemia (PML) protein is a potent growth suppressor and proapototic factor, whereas aberrant fusions of PML and retinoic acid receptor (RAR)-α are causal agents in human acute promyelocytic leukemia. Arsenic trioxide (As2O3) treatment induces apoptosis in acute promyelocytic leukemia cells through an incompletely understood mechanism. We report here that As2O3 treatment induces phosphorylation of the PML protein through a mitogen-activated protein (MAP) kinase pathway. Increased PML phosphorylation is associated with increased sumoylation of PML and increased PML-mediated apoptosis. Conversely, MAP kinase cascade inhibitors, or the introduction of phosphorylation or sumoylation-defective mutations of PML, impair As2O3-mediated apoptosis by PML. We conclude that phosphorylation by MAP kinase cascades potentiates the antiproliferative functions of PML and helps mediate the proapoptotic effects of As 2O3.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 389-401 |
| Number of pages | 13 |
| Journal | Cancer Cell |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2004 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Cell Biology
- Oncology
Cite this
Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. / Hayakawa, Fumihiko; Privalsky, Martin L.
In: Cancer Cell, Vol. 5, No. 4, 04.2004, p. 389-401.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis
AU - Hayakawa, Fumihiko
AU - Privalsky, Martin L.
PY - 2004/4
Y1 - 2004/4
N2 - The promyelocytic leukemia (PML) protein is a potent growth suppressor and proapototic factor, whereas aberrant fusions of PML and retinoic acid receptor (RAR)-α are causal agents in human acute promyelocytic leukemia. Arsenic trioxide (As2O3) treatment induces apoptosis in acute promyelocytic leukemia cells through an incompletely understood mechanism. We report here that As2O3 treatment induces phosphorylation of the PML protein through a mitogen-activated protein (MAP) kinase pathway. Increased PML phosphorylation is associated with increased sumoylation of PML and increased PML-mediated apoptosis. Conversely, MAP kinase cascade inhibitors, or the introduction of phosphorylation or sumoylation-defective mutations of PML, impair As2O3-mediated apoptosis by PML. We conclude that phosphorylation by MAP kinase cascades potentiates the antiproliferative functions of PML and helps mediate the proapoptotic effects of As 2O3.
AB - The promyelocytic leukemia (PML) protein is a potent growth suppressor and proapototic factor, whereas aberrant fusions of PML and retinoic acid receptor (RAR)-α are causal agents in human acute promyelocytic leukemia. Arsenic trioxide (As2O3) treatment induces apoptosis in acute promyelocytic leukemia cells through an incompletely understood mechanism. We report here that As2O3 treatment induces phosphorylation of the PML protein through a mitogen-activated protein (MAP) kinase pathway. Increased PML phosphorylation is associated with increased sumoylation of PML and increased PML-mediated apoptosis. Conversely, MAP kinase cascade inhibitors, or the introduction of phosphorylation or sumoylation-defective mutations of PML, impair As2O3-mediated apoptosis by PML. We conclude that phosphorylation by MAP kinase cascades potentiates the antiproliferative functions of PML and helps mediate the proapoptotic effects of As 2O3.
UR - http://www.scopus.com/inward/record.url?scp=1842785771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842785771&partnerID=8YFLogxK
U2 - 10.1016/S1535-6108(04)00082-0
DO - 10.1016/S1535-6108(04)00082-0
M3 - Article
VL - 5
SP - 389
EP - 401
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 4
ER -